Lisa Bance co-wrote this blog post with Kristyn Feldman.
This post is the first in a four-part series examining patient centricity within R&D.
The concept of patient centricity within drug development is far from novel, yet many pharmaceutical companies still struggle to put the patient at the center of their R&D efforts. In a recent article, we wrote about the need for pharmaceutical companies to become true partners in patients’ health. In fact, our research shows that engaging patients from the outset could lead to improved patient recruitment and retention and reduce R&D costs and timelines. Here’s the first step—one of four—that companies can take to start moving toward patient-centric drug development.